

# Helena Tavares De Sousa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12023477/publications.pdf>

Version: 2024-02-01

16  
papers

1,193  
citations

840776

11  
h-index

888059

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

2079  
citing authors

#	ARTICLE	IF	CITATIONS
1	Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2059-2073.e7.	4.4	4
2	Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2567-2576.e9.	4.4	12
3	Ileal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of Phenotype. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00330.	2.5	8
4	Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 169-175.	1.3	25
5	The new simplified MARIA score applies beyond clinical trials: A suitable clinical practice tool for Crohn's disease that parallels a simple endoscopic index and fecal calprotectin. <i>United European Gastroenterology Journal</i> , 2020, 8, 1208-1216.	3.8	21
6	Comparison of the Nancy Index With Continuous Geboes Score: Histological Remission and Response in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1021-1025.	1.3	18
7	Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 743-756.	1.3	5
8	Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986914.	3.2	4
9	Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. <i>Gut</i> , 2019, 68, 594-603.	12.1	83
10	New cross-sectional imaging in IBD. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 194-207.	2.3	18
11	Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in Ulcerative Colitis—the ACERTIVE study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw170.	1.3	22
12	Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation. <i>EBioMedicine</i> , 2017, 21, 123-130.	6.1	8
13	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 769-784.	1.3	876
14	Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 661-671.	3.2	16
15	Clinical performance of an infliximab rapid quantification assay. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 651-660.	3.2	16
16	Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 781-794.	3.2	15